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The potent antiangiogenic pigment epithelium-derived factor (PEDF) has shown promise against osteosarcoma, a tumour that
originates in the bone and metastasises to the lungs. Neurotrophic, antiangiogenic, antiproliferative, and antimetastatic properties
of PEDF have been attributed to a number of functional epitopes on the PEDF glycoprotein. StVOrth-2 (residues 78–102) and
StVOrth-3 (residues 90–114) are two PEDF-derived peptides based on these functional epitopes. StVOrth-2 has previously been
shown to inhibit osteosarcoma cell proliferation, while StVOrth-3 increased osteosarcoma cell adhesion to collagen I in vitro.
In this paper, we have evaluated systemically and continuously delivered StVOrth-2 and StVOrth-3 using a clinically relevant
murine model of osteosarcoma with spontaneous metastasis. Treatment with StVOrth-2 or StVOrth-3 with microosmotic pumps
was initiated after primary osteosarcoma was established in the tibia. While treatment with StVOrth-2 and StVOrth-3 did not
appear to aﬀect local tumour invasion, tumour necrosis or apoptosis, StVOrth-2 predominantly restricted the growth of primary
tumours,whileStVOrth-3restrictedtheburdenofpulmonarymetastaticdisease.Nopeptidecausedgrosstoxicityinmousetissues
as assessed by measuring weight of animals, serum biochemistry, and gross tissue observation. The diﬀerential eﬀects exhibited
by StVOrth-2 and StVOrth-3 in this orthotopic model of osteosarcoma may be related to the functional epitopes on the PEDF
glycoprotein that they represent.
1.Introduction
Pigment epithelium-derived factor (PEDF) is a 50kDa en-
dogenous glycoprotein that was ﬁrst discovered in 1991 as
a factor secreted by the pigment epithelium of the human
foetal eye [1]. PEDF was shown to promote diﬀerentiation
of retinoblastoma cells [2] and was implicated in a range
of eye pathologies including diabetic retinopathy, macular
degeneration, and retinitis pigmentosa and glaucoma [3].
PEDF is a potent antiangiogenic agent, more potent than
angiostatin, endostatin and thrombospondin-1 by endothe-
lial cell migration assay [4]. PEDF has also been shown to be
an antitumorigenic agent for malignancies including osteo-
sarcoma, melanoma, glioma, lung, breast, prostatic, ovarian
and pancreatic carcinomas [5].
Biochemical studies have enabled the identiﬁcation of
multiple functional epitopes for PEDF. The interactions
between these epitopes and receptors are likely to initi-
ate divergent signalling pathways for the diﬀerent cellu-
lar eﬀects of PEDF. Filleur et al. [6]ﬁ r s tc h a r a c t e r i s e d
34-mer (residues 24–57) and 44-mer (residues 58–101)
PEDF-derived peptides that conferred antiangiogenic and
neurotrophic activity, respectively. Additionally, another se-
quence, ERT (residues 79–94), showed both antiangiogenic
and diﬀerentiation activity. The properties of these peptides
were demonstrated in vitro by endothelial cell apoptosis
and chemotaxis assays and Y-79 retinoblastoma diﬀerenti-
ation assay. Using a subcutaneous tumour model and PC-
3 prostate cancer cells, expression of the 34mer peptide
reduced tumour microvascular density and induced tumour
cell apoptosis, eﬀects not demonstrated for the 44-mer
peptide [6]. The 34mer peptide restricted angiogenesis
through a c-jun-NH2 kinase (JNK-) dependent pathway
leading to NFATc2 deactivation and c-Flip antagonism [6].2 Journal of Biomedicine and Biotechnology
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Figure 1: StVOrth-2 and StVOrth-3 peptides. StVOrth-2 (highlighted in blue) consists of residues 78–102 of the parent PEDF sequence.
StVOrth-3 (highlighted in red) consists of residues 90–114. StVOrth-2 and StVOrth-3 have previously been shown to inhibit osteosarcoma
cell proliferation and promote osteosarcoma cell adhesion to collagen I in vitro,r e s p e c t i v e l y[ 7]. ∗ERT and 44-mer peptide sequences, as
described by Filleur et al. [6], overlap with the StVOrth-2 and StVOrth-3 sequences.
I na n o t h e rs t u d y ,f o u rd i ﬀerent PEDF-derived peptides,
termed StVOrth-1, StVOrth-2, StVOrth-3, and StVOrth-
4, consisting of PEDF residues 40–64, 78–102, 90–114,
and 387–411, respectively, were tested in vitro and in vivo
[7]. In vitro, StVOrth-2 was the most potent inhibitor
of SaOS-2 osteosarcoma cell proliferation, while StVOrth-
3 dramatically promoted SaOS-2 adhesion to collagen I.
StVOrth-4 inhibited SaOS-2 cell invasion through Matrigel.
StVOrth-1,-2,and-3allinducedosteoblasticdiﬀerentiation.
StVOrth-3 and StVOrth-4 reduced VEGF expression in
SaOS-2 osteosarcoma cells. StVOrth-2 and StVOrth-3 were
then evaluated in vivo using an orthotopic murine model
of osteosarcoma. Notably, StVOrth-2 (residues 78–102) and
StVOrth-3 (residues 90–114) possessed sequences that over-
lapped with the 44-mer (residues 58–101) and ERT (residues
79–94) sequences described by Filleur et al. [6]( Figure 1).
Both StVOrth-2 and StVOrth-3 restricted osteosarcoma
tumourgrowthandinhibitedthedevelopmentofpulmonary
metastaseswhenSaOS-2cellsweretreatedpriortointratibial
injection.
The ﬁndings of both Filleur et al. [6]a n dE ke ta l .[ 7]
provide some insight into how PEDF structure relates to
its multidimensional ability to restrict tumour progression.
However, the study design and methods of peptide delivery
used in these models make it diﬃcult to extrapolate the
ﬁndings forhumanuse. Filleuretal. [6]usedas ubcu taneous
tumour model with transfected PC-3 cells to demonstrate
the diﬀerential eﬀects of the 34-mer and 44-mer PEDF-
derived peptides. Gene therapies have yet to be proven safe
for human application, making it unlikely that they will be
used for osteosarcoma therapy in the near future [8]. Ek
et al. [7] used the SaOS-2 osteosarcoma cell line to achieve
a spontaneously metastasizing murine model of orthotopic
osteosarcoma. SaOS-2 cells were treated with StVOrth-2
and StVOrth-3 peptides prior to intraosseous injection,
thus facilitating early uptake of peptides and change in
phenotype. In order to evaluate the true eﬃcacy of PEDF-
derivedpeptidesagainstestablishedosteosarcoma,treatment
should be delayed until after the establishment of primary
tumours.Thiswouldbettersimulatetheclinicalpresentation
and treatment of osteosarcoma in humans.
2.MaterialsandMethods
2.1. Cells and Culture Conditions. The SaOS-2 human os-
teosarcoma cell line (American Tissue Culture Collection,
Manassas, VA, USA) was cultured in complete medium,
CM, at 37◦C and in humidiﬁed 5% CO2. CM consisted of
MEM-Alpha+GlutaMAX (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% foetal bovine serum (Invitrogen,
Carlsbad, CA, USA) and 1% antibiotic-antimycotic (Invitro-
gen, Carlsbad, CA, USA). Exponentially growing cells, with
passagenumberalwayslessthan20,wereusedforthestudies.Journal of Biomedicine and Biotechnology 3
2.2. Establishment of the Orthotopic Model of Osteosarcoma.
5-week-old Balb/c nude mice were purchased from the
Animal Resource Centre, Perth, Australia and were housed
at the St Vincent’s Hospital BioResources Centre under
PC2 pathogen-free conditions. Animal ethics approval was
obtained from the St Vincent’s Hospital Melbourne Animal
Ethics Committee. A 50% concentration of Matrigel was
used to dilute SaOS-2 osteosarcoma cells to a concentration
of 2 × 106 cells/mL. Following anaesthesia with intraperi-
toneal ketamine (100mg/kg) and xylazine (10mg/kg), a 27-
gauge needle was introduced into the left tibia of each mouse
using a gentle drilling motion in order to avoid iatrogenic
fracture [9], and a volume of 10μL of SaOS-2/Matrigel
solution was injected. Postinjection, the needle was retracted
slowly to prevent backﬂow of injectate.
Tumour growth and animal weights were monitored
twice weekly until the endpoint of the study. Anteroposterior
(AP) and lateral (L) dimensions of limbs were recorded
using digital callipers. Volumes were calculated from these
dimensions using the formula 4/3π[1/4(AP+L)]2 [7]. The
contralateral nontumour-bearing limb was used as a control
to calculate actual tumour volume.
Primary orthotopic tumours were apparent at day 20
after SaOS-2 inoculation, when average tumour volume
was 22.5mm3, at which point mice were randomised into
treatment groups each consisting of four mice. As outlined
below, these groups received either: (1) sterile water as
control, (2) StVOrth-2 at 50μg/kg/day, (3) StVOrth-2
at 500μg/kg/day, (4) StVOrth-3 at 50μg/kg/day, or (5)
StVOrth-3 at 500μg/kg/day.
2.3. Delivery of PEDF-Derived Synthetic Peptides. PEDF-
derived peptides, StVOrth-2 (residues 78–102) and StVOrth-
3 (90–114), were designed and sourced previously according
to the procedure outlined by Ek et al. [7]. This paper refers
to the full-length human PEDF sequence, and amino acid
numbering is based on those sequences listed in GenBank
(National Institutes of Health). StVOrth-2 is the aminoacid
sequence 78VLLSP LSVAT ALSAL SLGAE QRTES102.
StVOrth-3 is the sequence 90SALSL GAEQR TESII HRALY
YDLIS114. High-performance liquid chromatography
(HPLC) and mass spectrometry was used to conﬁrm the
purity of these peptides. Ek et al. [7] showed that StVOrth-2
inhibited SaOS-2 osteosarcoma cell proliferation, while
StVOrth-3 inhibited SaOS-2 osteosarcoma cell adhesion to
collagen I in vitro. StVOrth-2 and StVOrth-3 sequences over-
lap with the 44-mer (residues 58–101), and ERT (residues
79–94) sequences described by Filleur et al. [6]( Figure 1).
Sustained delivery of StVOrth-2, StVOrth-3, or sterile
water (negative control, placebo) was achieved by intraperi-
toneallyimplantedAlzetmicroosmoticpump(DurectCorp.,
Cupertino, CA, USA). Pumps were aseptically ﬁlled with
the diﬀerent treatments and surgically implanted within
the peritoneal cavity of animals for systemic delivery. This
surgery was performed at day 20 after SaOS-2 injection.
The mean pumping rate for the Alzet microosmotic pump
(model1002)is0.25μL/hrover14days,asdeterminedbythe
manufacturer. StVOrth-2 and StVOrth-3 were administered
at 50μg/kg and 500μg/kg daily doses. Sterile water was used
as diluent for StVOrth-2 and StVOrth-3.
The human physiological serum concentration of PEDF
ranges between 4ng/mL (80pM) to 15μg/mL (300nM) [10–
15]. In one study, inhibition of vessel formation in ischemia-
induced retinopathy was achieved at a 50nM concentration
[16]. The 50μg/kg and 500μg/kg doses used in the present
study are equivalent to 1μg/mL (20nM) and 10μg/mL
(200nM) concentrations of PEDF, respectively, which lies
within the range mentioned above. This assumes an average
mouse weight of 20 grams and an average blood volume
of 1mL [17]. It is known that the pumps are capable
of delivering a steady state quantity of peptides into the
abdominalcavity[18,19],whichwilleventuallybetakeninto
the microvasculature supplying the abdominal region.
2.4.StudyEndpointandTissueAnalysis. Tumours had grown
to a disabling size for control animals at day 34 after SaOS-
2 inoculation as expected. This was the humane endpoint of
the study, and all animals were euthanized under anaesthesia
by cervical dislocation at this time. Following this, tumour-
bearing limbs, lungs, hearts, small intestines, and skin
were harvested for examination. All specimens were ﬁxed
in 4% paraformaldehyde, followed by paraﬃn embedding.
Blood samples were obtained after cervical dislocation and
dissection through the thoracic cage and were immediately
treated with anticoagulants. Aﬀected limbs were X rayed
at 35kV for 30s using a cabinet system (Faxitron Corp.,
Wheeling, IL, USA).
Blood collected after euthanasia was analysed for renal
and hepatic biochemical parameters (serum creatinine, ala-
nine transaminase (ALT), and aspartate transferase (AST))
using a Sysmex XE2100 instrument [20]. Tissues were
embedded in paraﬃn prior to histological preparation
and analysis. For preparation of paraﬃn sections, 4μm
sections of tumours and viscera were cut by microtome.
Tumours were sectioned to provide an en face surface for the
quantiﬁcation of per cent tumour necrosis and apoptosis.
Primary tumours, lungs, heart, small intestine, and skin
sections were dehydrated through an ethanol series followed
by xylene, then stained with haematoxylin and eosin.
A terminal dUTP nick end labelling (TUNEL) assay kit
(Promega, Madison, WI, USA) was used to detect apoptotic
cells in primary tumours [21]. Pertex mounting agent was
used to seal coverslips to slide sections, and all tissues were
observed using a Nikon Eclipse TE2000-U microscope
(Nikon, Lidcombe, NSW, Australia) and photographed with
SPOT Advanced software (SciTech, Aurora, IL, USA).
The eﬀect of intraperitoneal StVOrth-2 and StVOrth-3
on the development of pulmonary metastatic disease was
examined histologically. Lungs were sectioned to achieve the
greatest cross-sectional area and stained with haematoxylin
and eosin. Micrometastases were identiﬁed by systematically
scanning lung sections under 20x magniﬁcation. Discernible
clusters of metastatic cells at this magniﬁcation were counted
as micrometastases. Ten metastatic lesions were then ran-
domly selected from each treatment group for measurement
of cross-sectional areas.4 Journal of Biomedicine and Biotechnology
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Figure 2: (a) Animal weights recorded at days 20, 23, 27, 30, and 34 after SaOS-2 intratibial injection. There was no signiﬁcant weight loss
compared to control. (b) Biochemical analysis of serum collected postmortem (±SEM). There was no evidence of renal or hepatic toxicity.
2.5. Statistical Methods and Imaging Software. One-way and
two-wayANOVAanalyseswithBonferronimultiplecompar-
isons test were used where appropriate (GraphPad Prism 5
for Mac OS X). ImageJ (Version 1.45j, National Institutes
of Health, USA) was used for all image analysis. Means and
standard errors were calculated for all data collected.
3. Results
3.1. Potential Systemic Side Eﬀects of PEDF-Derived Pep-
tides. Mice were studied for potential systemic side aﬀects
associated with delivery of StVOrth-2 (residues 78–102)
and StVOrth-3 (residues 90–114) (see Figure 1). Mice were
regularly monitored during the study for signs of distress
and animal weights were recorded twice weekly. All mice
remained well for the duration of the study, and no signiﬁ-
cant weight loss compared to control was observed (two-way
ANOVA) (Figure 2(a)).
Serum, hearts, lungs, skin, and small intestines were col-
lected postmortem for histological examination. No features
of cytotoxicity [22] were evident in these tissues, in either
control or peptide-treated groups. Renal and hepatic serum
biochemistry parameters were within physiological limits
[23] for all treatment groups (Figure 2(b)).
3.2. Systemically Delivered StVOrth-2 Inhibits Osteosarcoma
Tumour Growth. Orthotopic osteosarcoma in this murine
model was treated with systemically delivered StVOrth-2 and
StVOrth-3. Microosmotic pumps, continuously delivering
StVOrth-2 and StVOrth-3 at daily doses of 50μg/kg and
500μg/kg, were implanted in the peritoneal cavities of mice
at day 20 of the study. Tumours were well established at
this time with an average tumour volume of 22.5mm3
(±1.7SEM).
Sustained delivery of StVOrth-2 at both doses caused a
signiﬁcant reduction in primary tumour volume at the study
endpoint. 50μg/kg and 500μg/kg StVOrth-2 caused 49.7%
and 50.9% reductions in tumour volume, respectively, at day
34 (P<0.01, two-way ANOVA with Bonferroni multiple
comparisonstest)(Figures3(a)and3(b)).AsigniﬁcanteﬀectJournal of Biomedicine and Biotechnology 5
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Figure 3:SystemicallydeliveredStVOrth-2inhibitsgrowthoforthotopicosteosarcoma.(a)Photomicrographsofmiceshowinglefttumour-
bearinghindlimbs.(b)Tumourvolumesrecordedatdays20,23,27,30,and34afterSaOS-2intratibialinjection(±SEM). ∗P<0.01,two-way
ANOVA.
was not seen before the day 34 time point, and there was no
statistical diﬀerence between the two doses of StVOrth-2.
By comparison, the therapeutic eﬀect of StVOrth-2 on
primary tumour volume was unable to be replicated by
systemic StVOrth-3 therapy. Despite achieving 30.1% and
40.0% reductions in primary tumour volume at day 34 with
50μg/kg and 500μg/kg StVOrth-3, respectively, these results
did not achieve statistical signiﬁcance (two-way ANOVA)
(Figures 3(a) and 3(b)).
3.3. Tumour Invasion, Necrosis, and Apoptosis. Plain radio-
graphs obtained after disarticulation of tumour-bearing
limbs showed extensive soft tissue invasion and osteolysis for
all animals (Figure 4). Invasion of surrounding structures,
tumour necrosis, and apoptosis were assessed histologically.
Treatment with either StVOrth-2 or StVOrth-3, at both
50μg/kg and 500μg/kg doses, did not aﬀect orthotopic
tumour invasion of the surrounding structures. All tumour-
bearing animals showed invasion of skeletal muscles and6 Journal of Biomedicine and Biotechnology
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Figure 4: Tumour invasion. Plain radiographs (left) of tumour-
bearing limbs show extensive osteolysis of proximal tibiae and soft
tissue extension for all treatment groups. Haematoxylin and eosin-
stainedsectionsoforthotopictumour(right)showtumourcells(T)
invading bone (B) and skeletal muscle (M).
osteolysis on both sides of the adjacent joint. Tumour
cells were clearly seen breaching the epiphyseal cartilage
(Figure 4).
Treatment with StVOrth-2 or StVOrth-3 did not aﬀect
the degree of tumour necrosis. Per cent tumour necrosis was
statistically equivalent for both StVOrth-2 and StVOrth-3
at either dose (one-way ANOVA). Similarly, treatment with
StVOrth-2 or StVOrth-3 did not appear to aﬀect tumour
cell apoptosis. The percentage of TUNEL-positive staining
tumour was found to be statistically equivalent across
treatment groups (one-way ANOVA) (Table 1).
3.4. StVOrth-3 Restricts the Burden of Pulmonary Metastatic
Disease. This SaOS-2 orthotopic model of osteosarcoma
gives rise to spontaneous pulmonary metastases, and the
burden of metastatic disease was assessed histologically post-
mortem. Haematoxylin- and eosin-stained sections of lung
tissue were examined under 20x objective. The numbers
of micrometastases per lung section were enumerated, and
treatment with StVOrth-2 or StVOrth-3, at both 50μg/kg
and 500μg/kg doses, had no eﬀect on the number of lesions
observed (one-way ANOVA) (Figures 5(a) and 5(b)).
Treatment with StVOrth-3 did, however, cause a signif-
icant reduction in the size of micrometastatic lesions. The
meancross-sectionalareaofamicrometastasiswas0.19mm2
and 0.29mm2 for 50μg/kg and 500μg/kg StVOrth-3. This
represented a 79% and 68.2% reduction in area compared to
animals that received sterile water as control (P<0.05, one-
way ANOVA analysis with Bonferroni multiple comparisons
test). Treatment with 50μg/kg and 500μg/kg StVOrth-2
resulted in mean cross-sectional areas of 0.68mm2 and
1.02mm2 respectively. These results, however, were not
statistically signiﬁcant (Figure 5(c)).
4. Discussion
Ek et al. [7] evaluated four PEDF-derived peptides based
on the known functional epitopes of the PEDF glycopro-
tein. StVOrth-2 (residues 78–102) predominantly restricted
SaOS-2 osteosarcoma cell proliferation and StVOrth-3
(residues90–114)increasedadhesiontocollagenI.Bothpep-
t i d e sr e s t r i c t e dg r o w t ho fp r i m a r yo s t e o s a r c o m aa n dt h e
development of pulmonary metastases in vivo [7]. In this
study we aimed to assess systemically delivered StVOrth-2
and StVOrth-3 as treatments for established osteosarcoma
(both primary and secondary disease) and to evaluate the
therapeutic safety of these peptides. We utilised the same
orthotopic murine model of osteosarcoma described by
Ek et al. [7] and delivered the StVOrth-2 and StVOrth-3
peptides systemically via an intraperitoneal microosmotic
pump. Treatment was delayed until after the macroscopic
appearance of primary osteosarcoma. Using this optimised
model, diﬀerential eﬀects on tumour growth and metastasis
were demonstrated for StVOrth-2 and StVOrth-3, respec-
tively.
Systemic delivery of StVOrth-2 restricted the volume
of primary osteosarcoma. We observed 49.7% and 50.9%
reductions in tumour volume with 50μg/kg and 500μg/kg
StVOrth-2 treatments, respectively. Ek et al. [7] showed
a reduction of more then 30% when these peptides were
administered prior to SaOS-2 inoculation. It is interesting
that StVOrth-2 caused greater inhibition of tumour growth
than StVOrth-3. Ek et al. [7] showed that StVOrth-2
had a signiﬁcant antiproliferative eﬀect on SaOS-2 cells
in vitro, while StVOrth-3 did not exhibit this eﬀect. TheJournal of Biomedicine and Biotechnology 7
Table 1: Tumour per cent necrosis and apoptosis as determined on haematoxylin and eosin-stained and TUNEL-stained sections of
orthotopic tumour, respectively.
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Figure 5: Systemically delivered StVOrth-3 inhibits progression of pulmonary metastatic disease. (a) Haematoxylin- and eosin-stained
sections of lung tissue show micrometastases (arrows) disrupting the native alveolar architecture. Metastatic lesions were predominately
subpleural and around larger airways. (b) Number of pulmonary micrometastases per lung section at 20x magniﬁcation (±SEM). (c) Cross-
sectional areas of pulmonary micrometastases (±SEM). ∗P<0.05, one-way ANOVA.8 Journal of Biomedicine and Biotechnology
molecular mechanisms exploited by StVOrth-2 to achieve its
antitumour eﬀect are yet to be characterised.
TreatmentwithStVOrth-2andStVOrth-3didnotappear
to aﬀect local tumour invasion, tumour necrosis, or apop-
tosis. Tumour cells were observed invading the soft tissues
and destroying the local bony architecture in all animals,
independent of treatment type. Although groups receiving
StVOrth-2 and StVOrth-3 were unable to be statistically
diﬀerentiated based on tumour cell necrosis and apoptosis,
it was evident that the percentages of tumour necrosis
and apoptosis were proportional to tumour volume. This
SaOS-2 orthotopic model of osteosarcoma gives rise to
large and rapidly growing tumours. By delaying treatment
until tumours were palpable, it is possible that tumour
energy requirements exceeded capacity of the vascular sup-
ply, leading to spontaneous necrosis and apoptosis of the
tumour core. Such areas of necrosis and potential apoptosis
are commonly observed in clinical tumours at our centre
(personal observation).
Ek et al. [7] showed that both StVOrth-2 and StVOrth-3
dramatically restricted spontaneous pulmonary metastases,
despite exhibiting diﬀerential eﬀects on cell proliferation and
collagen I invasion in vitro. The authors hypothesized that
distinctantitumourpathwaysmayexplaintheseresults.With
this is mind, the role of these peptides in the metastatic
process was again investigated. Pulmonary micrometastases
were quantiﬁed under low-power microscopy, rather than
thepostmortemmacroscopicmethodutilisedbyEketal.[7].
Cross-sectional areas of metastatic lesions were quantiﬁed
to estimate the burden of pulmonary disease. StVOrth-3
showed a dramatic 79% reduction in pulmonary burden
of disease, an eﬀect consistent with the observation that
StVOrth-3predominantlyrestrictsadhesiontocollagenI[7].
StVOrth-3 may critically inhibit the metastatic cascade via
this mechanism; however, one cannot rule out a direct eﬀect
onpulmonarylesionsviasystemicdelivery.Themethodused
here for evaluating metastatic lesions is an improvement
upon that used by Ek et al. [7].
The ﬁnal aim of this study was to perform a preliminary
evaluation of therapeutic safety. Ek et al. [7] showed that
both StVOrth-2 and StVOrth-3 possess a moderate ability to
inhibit VEGF expression by SaOS-2 cells. For antiangiogenic
agents to be of clinical use, it is critical that these eﬀects are
not achieved at the expense of homeostatic processes such
as wound healing and inﬂammation. Serum analysis and
histology of harvested viscera did not show any evidence of
treatment-relatedtoxicity.Allanimalsappearedtobehealthy
andexhibitednormalgrazingandbehaviourfortheduration
of the study. We also did not note any gross diﬀerences in
surgical wound healing between the treatment groups.
We also clarify that both StVOrth-2 and StVOrth-3 were
nonimmunogenic, despite their length (25-mer). There are
two direct items that need to be highlighted: (i) both pep-
tides were eﬀective in vivo when administered systemically
(despite any potential immunogenicity), and (ii) we did not
notice any inﬂammation- or immunostimulation-mediated
exudates around the region of the pump outlet. If the
peptides were immunogenic, this would be clearly visible
in these mice, as we have noticed this before with other
anticancer agents (Dass, unpublished data).
StVOrth-2hasbeenshowntobemosteﬀectiveatinhibit-
ing primary tumour growth while StVOrth-3 predominantly
restricts progression of pulmonary metastases. The molecu-
lar mechanisms utilised by these peptides are yet to be fully
studied and elucidated. Mechanistic studies have focused on
the parent PEDF glycoprotein that interacts with regulatory
pathways that induce apoptosis of both endothelial and
tumourcells[24].In vitro andinvivo studieshaveimplicated
the Fas-FasL death receptor pathway [25–27], Bcl-2 family
proteins [28], caspases, and c-Flip [29]. The current study
did not look at molecular markers in vivo,a p a r tf r o m
the blood analyses for creatinine, alanine transaminase and
aspartate transferase. In vitro though, we have previously
examined several biological and molecular features of PEDF-
based peptide treatment of SaOS-2 cells [7]. In that earlier
study, StVOrth-2 was the most potent inhibitor of SaOS-
2 osteosarcoma cell proliferation, while StVOrth-3 dramat-
ically promoted SaOS-2 adhesion to collagen I. StVOrth-2
and -3 induced osteoblastic diﬀerentiation, while StVOrth-
3 and StVOrth-4 reduced VEGF expression in SaOS-2 cells.
The current set of in vivo results, from a focussed pharma-
codynamic study, reﬂect quite closely what we expected from
the earlier in vitro study.
Peptides have a number of advantages as targeted
therapies,beingneithergenotoxicnorgenotypespeciﬁc[30].
Peptides haveexcellenttissue penetrationandbindwithhigh
aﬃnity and speciﬁcity to therapeutic targets [31–33]. In this
study we demonstrated pronounced diﬀerences in action
between the two peptides and this begs the question as to
precisely which are the aminoacid sequences essential for
these eﬀects. StVOrth-2 consisted of 78LSPLS VATAL SALSL
GAEQR TESII102, and StVOrth-3 consisted of 90LSLGA
EQRTE SIIHR ALYYD LISSP114. The overlapping 90LSL
GAEQR TESII102 sequence may in fact be nonessential for
the described eﬀects. Further studies utilising the shortened,
nonoverlapping sequences of StVOrth-2 and StVOrth-3 are
the next logical step. Beyond this, development of a hybrid
version of StVOrth-2 and StVOrth-3 peptides may then be
possible, leading potentially to a compound that possesses
antitumorigenic and antimetastatic properties superior to
that of the parent PEDF glycoprotein and hopefully of the
individual peptides used in isolation.
Multiple functional epitopes for PEDF have been
identiﬁed, as well as several distinct PEDF receptors [34, 35].
Filleur at al. [6] ﬁrst characterised 34-mer (residues 24–57)
and 44-mer (residues 58–101) PEDF-derived peptides
that conferred antiangiogenic and neurotrophic activity,
respectively. Additionally, another sequence, ERT (residues
79–94), showed both antiangiogenic and diﬀerentiation
activity. Mirochnik et al. [26] derived three diﬀerent shorter
peptides from the 34-mer PEDF-based peptide [6]a n d
demonstrated that a 18-mer peptide was in fact able to
inhibit angiogenesis and the growth of prostate cancer in
mice. Amaral and Becerra [36] showed that the 34mer
peptide [6] suppresses choroidal neovascularization fol-
lowing subconjunctival administration. The interactions
between these various identiﬁed epitopes and receptorsJournal of Biomedicine and Biotechnology 9
are likely to initiate divergent signalling pathways for the
diﬀerent cellular eﬀects of PEDF. We did not identify which
PEDF receptor the peptides were interacting with in this
study. There is also the possibility that the peptides may
be interacting with other cell surface ligands given that the
quaternary structure of the peptides is expected to be very
diﬀerent from the full length PEDF protein.
5. Conclusions
This study provides a number of insights into the mecha-
nismsoftheantiosteosarcomaactivityofPEDFandsupports
the use of PEDF-derived peptides as therapeutic agents.
StVOrth-2 (residues 78–102) primarily restricts growth of
primary osteosarcoma, while StVOrth-3 (residues 90–114)
restricts pulmonary metastatic disease. These ﬁndings are
particularly signiﬁcant given that the orthotopic model of
osteosarcoma gives rise to large and rapidly growing tum-
ours, and that these peptides were administered at a stage of
advanced disease.
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